Evidence map›Paper›PMID 37372999›Full record

ReviewInternational journal of molecular sciences2023

Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming.

Raphael P Viscidi, Treva Rowley, Ioannis Bossis

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Raphael P ViscidiDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.ORCID 0000-0002-7906-8002
Treva RowleyDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.
Ioannis BossisDepartment of Animal Production, School of Agricultural Sciences, Forestry & Natural Resources, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Johns Hopkins Medicine · USAristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safe and effective T cell vaccines are needed for the treatment or prevention of cancers as well as infectious agents where vaccines for neutralizing antibodies have performed poorly. Recent research highlights an important role for tissue-resident memory T cells (T

Indexed as

Cancer VaccinesProstatic NeoplasmsVaccines, Virus-Like ParticleAnimalsAntibodies, ViralCapsid ProteinsCD8-Positive T-LymphocytesCross-PrimingCysteineHumansMaleMiceAntibodies, ViralCancer VaccinesCapsid ProteinsCysteineVaccines, Virus-Like Particlecancer vaccinecross-primingpapillomavirusvaccinevirus-like particle (VLP)

Identifiers

PMID37372999
PMCPMC10298155
OpenAlexW4380051632

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.